Falla hepática aguda
DOI:
https://doi.org/10.52784/27112330.112Palabras clave:
falla hepática aguda, hepatitis fulminante, trasplante hepático, necrosis hepática masiva.Resumen
La falla hepática aguda es la pérdida súbita de la función hepática en un corto plazo en un paciente sin enfermedad hepática previa, que se acompaña de coagulopatía y encefalopatía. Es una entidad rara con una incidencia muy baja que afecta especialmente a personas jóvenes. La principal causa en países desarrollados es la toxicidad por acetaminofén, mientras que en los países subdesarrollados son las hepatitis virales. El curso natural de la enfermedad es la progresión rápida a muertepor falla orgánica multisistémica, sepsis o edema cerebral. Después del diagnóstico, los pacientes deben remitirse tempranamente a la unidad de cuidado intensivo y a centros que ofrezcan trasplante hepático. La supervivencia sin trasplante hepático hasta hace pocos años era menor al 15%; sin embargo, en la actualidad puede ser hasta del 50%, dependiendo de la causa, y está relacionada con tratamientos específicos, la disponibilidad de trasplante hepático y una atención óptima en las unidades de cuidados intensivos. El trasplante hepático se constituye en el tratamiento de elección para los pacientes con falla hepática aguda y criterios de mal pronóstico del King’s College.
Descargas
Referencias bibliográficas
Trey C, Davidson CS. The management of fulminant hepatic failure. In: Popper H, Schaffner F, eds. Progress in Liver Diseases. New York; Grune & Stratton, 1970: p. 282-298.
Bower W, Johns M, Margolis H, Williams I, Bell B. Population-based surveillance for acute liver failure. Am J Gastroenterol 2007;102:2459-2463.
Escorsell A, Mas A, de la Mata M, and the Spanish Group for the Study of Acute Liver Failure. Acute liver failure in Spain: Analysis of 267 cases. Liver Transpl 2007;13:1389-1395. https://doi.org/10.1002/lt.21119.
Polson J, Lee W. AASLD position paper: The management of acute liver failure. Hepatology 2005;41:1179-1197. https://doi.org/10.1002/hep.20703.
O’Grady J, Schalm SW, Williams R. Acute liver failure: Redefining the syndromes. Lancet 1993;342:273-275. https://doi.org/10.1016/0140-6736(93)91818-7.
Rakela J, Lange SM, Ludwig J, Baldus WP. Fulminant hepatitis: Mayo Clinic experience with 34 cases. Mayo Clin Proc 1985;60:289-292. https://doi.org/10.1016/S0025-6196(12)60534-5.
Ostapowicz G, Fontana R, Schiødt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-54. https://doi.org/10.7326/0003-4819-137-12-200212170-00007.
Bernal W, Hyyrylainen A, Gera A, Audimoolam V, McPhail M, Auzinger G, et al. Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. J Hepatol 2013;59:74-80. https://doi.org/10.1016/j.jhep.2013.02.010.
O’Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-445. https://doi.org/10.1016/0016-5085(89)90081-4.
Acharya SK, Batra Y, Hazari S, Choudhury V, Panda SK, Dattagupta S. Etiopathogenesis of acute hepatic failure: Eastern versus western countries. J Gastroenterol Hepatol 2002;17:S268-S273. https://doi.org/10.1046/j.1440-1746.17.s3.12.x.
Pinna AD, Rakela J, Demetris AJ, Fung JJ. Five cases of fulminant hepatitis due to herpes simplex virus in adults. Dig Dis Sci 2002;47:750-754. https://doi.org/10.1023/A:1014779614525.
Ronan BA, Agrwal N, Carey EJ, De Petris G, Kusne S, Seville MT, et al. Fulminant hepatitis due to human adenovirus. Infection 2014;42:105-111. https://doi.org/10.1007/s15010-013-0527-7.
Bjornsson E, Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis 2006;38:33-38. https://doi.org/10.1016/j.dld.2005.06.004.
Wai CT, Tan BH, Chan CL, Sutedja DS, Lee YM, Khor C, et al. Drug-induced liver injury at an Asian center: A prospective study. Liver Int 2007;27:465-474. https://doi.org/10.1111/j.1478-3231.2007.01461.x.
Bernal W, Wendon J. Acute liver failure. N Engl J Med 2013;369:2525-2534. https://doi.org/10.1056/NEJMra1208937
Lee W, Larson A, Stravitz R. The management of acute liver failure: Update 2011. Hepatology, Supplement September 2011.
Stravitz RT, Kramer AH, Davern T, Shaikh AO, Caldwell SH, Mehta RL, et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med 2007;35:2498-2508. https://doi.org/10.1097/01.CCM.0000287592.94554.5F.
Harrison PM, Wendon JA, Gimson AE, Alexander GJ, Williams R. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med 1991;324:1852-1857. https://doi.org/10.1056/NEJM199106273242604.
Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009;137:856-864. https://doi.org/10.1053/j.gastro.2009.06.006.
Tillmann HL, Hadem J, Leifeld L, Zachou K, Canbay A, Eisenbach C, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006;13:256-263. https://doi.org/10.1111/j.1365-2893.2005.00695.x.
Kumar M, Satapathy S, Monga R, Das K, Hissar S, Pande C, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007;45:97-101. https://doi.org/10.1002/hep.21486.
Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl 2007;13:953-955. https://doi.org/10.1002/lt.21088.
Ichai P, Duclos-Vallee JC, Guettier C, Hamida SB, Antonini T, Delvart V, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007;13:996-1003. https://doi.org/10.1002/lt.21036.
Ichai P, Afonso AM, Sebagh M, Gonzalez ME, Codés L, Azoulay D, et al. Herpes simplex virus associated acute liver failure: A difficult diagnosis with a poor prognosis. Liver Transpl 2005;11:1550-1555. https://doi.org/10.1002/lt.20545.
Mohsenin V. Assessment and management of cerebral edema and intracranial hypertension in acute liver failure. J Crit Care 2013;28:783-791. https://doi.org/10.1016/j.jcrc.2013.04.002.
Kandiah P, Olson J, Subramanian RM. Emerging strategies for the treatment of patients with acute hepatic failure. Curr Opin Crit Care 2016;22:142-151. https://doi.org/10.1097/MCC.0000000000000291.
Bhatia V, Batra Y, Acharya SK. Prophylactic phenytoin does not improve cerebral edema or survival in acute liver failure: A controlled clinical trial. J Hepatol 2004;41:89-96. https://doi.org/10.1016/j.jhep.2004.03.017.
Davenport A, Will EJ, Davidson AM. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med 1993;21:328-338. https://doi.org/10.1097/00003246-199303000-00007.
Rolando N, Philpott-Howard J, Williams R. Bacterial and fungal infection in acute liver failure. Semin Liver Dis 1996;16:389-402. https://doi.org/10.1055/s-2007-1007252.
Rolando N, Harvey F, Brahm J, Philpott-Howard J, Alexander G, Gimson A, et al. Prospective study of bacterial infection in acute liver failure: An analysis of fifty patients. Hepatology 1990;11:49-53. https://doi.org/10.1002/hep.1840110110.
Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000;32:734-739. https://doi.org/10.1053/jhep.2000.17687.
Shami VM, Caldwell SH, Hespenheide EE, Arseneau KO, Bickston SJ, Macik BG. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl 2003;9:138-143. https://doi.org/10.1053/jlts.2003.50017.
Wendon J, Lee W. Encephalopathy and cerebral edema in the setting of acute liver failure: pathogenesis and management. Neurocrit Care 2008;9:97-102. https://doi.org/10.1007/s12028-008-9123-6.
Bernal W, Hall C, Karvellas CJ, Auzinger G, Sizer E, Wendon J. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology 2007;46:1844-1852. https://doi.org/10.1002/hep.21838.
Blei AT, Olafsson S, Webster S, Levy R. Complications of intracranial pressure monitoring in fulminant hepatic failure. Lancet 1993;341:157-158. https://doi.org/10.1016/0140-6736(93)90016-A.
Munoz SJ. Difficult management problems in fulminant hepatic failure. Semin Liver Disease 1993;13:395-413. https://doi.org/10.1055/s-2007-1007368.
Lidofsky SD, Bass NM, Prager MC, Washington DE, Read AE, Wright TL, et al. Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology 1992;16:1-7. https://doi.org/10.1002/hep.1840160102.
Donovan JP, Shaw BW, Langnas AN, Sorrell MF. Brain water and acute liver failure: the emerging role of intracranial pressure monitoring. Hepatology 1992;16:267-268. https://doi.org/10.1002/hep.1840160138.
Murphy N, Auzinger G, Bernel W, Wendon J. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology 2004;39:464-70. https://doi.org/10.1002/hep.20056.
Canalese J, Gimson AES, Davis C, Mellon PJ, Davis M, Williams R. Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure. Gut 1982;23:625-629. https://doi.org/10.1136/gut.23.7.625.
Bernal W, Murphy N, Brown S, Whitehouse T, Nissen P, Hauerberg J, et al. A multicentre randomized controlled trial of moderate hypothermia to prevent intracranial hypertension in acute liver failure. J Hepatol 2016;65:273-279. https://doi.org/10.1016/j.jhep.2016.03.003.
Patel P, Okoronkwo N, Pyrsopoulos NT. Future approaches and therapeutic modalities for acute liver failure. Clin Liver Dis 2018;22:419-427. https://doi.org/10.1016/j.cld.2018.01.011.
Saliba F, Camus C, Durand F, Mathurin P, Letierce A, Delafosse B, et al. Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: A randomized, controlled trial. Ann Intern Med 2013;159:522-531. https://doi.org/10.7326/0003-4819-159-8-201310150-00005.
Larsen FS, Schmidt LE, Bernsmeier C, Rasmussen A, Isoniemi H, Patel V, et al. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial. J Hepatol 2016;64:69-78. https://doi.org/10.1016/j.jhep.2015.08.018.
Bismuth H, Samuel D, Castaing D, Adam R, Saliba F, Johann M, et al. Orthotopic liver transplantation in ful-minant and subfulminant hepatitis. The Paul Brousse experience. Ann Surg 1995;222:109-119. https://doi.org/10.1097/00000658-199508000-00002.
Schmidt L, Larsen F. MELD score as a predictor of liver failure and death in patients with acetaminophen-induced liver injury. Hepatology 2007;45:789-96. https://doi.org/10.1002/hep.21503.
O'Grady JG, Alexander GJ, Thick M, Potter D, Calne RY, Williams R. Outcome of orthotopic liver transplantation in the aetiological and clinical variants of acute liver failure. Q J Med 1988;68:817-824.
Germani G, Theocharidou E, Adam R, Karam V, Wendon J, O'Grady J, et al. Liver transplantation for acute liver failure in Europe: Outcomes over 20 years from the ELTR database. J Hepatol 2012;57:288-296. https://doi.org/10.1016/j.jhep.2012.03.017.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
La política de reconocimiento de autoría de Hepatología se basa en los criterios indicados por el ICMJE para conferir crédito de un trabajo a una persona, a la vez que se le atribuye responsabilidad por la publicación del mismo.
